Treatment of rosacea using radiofrequency microneedling
Split-Face Comparison of 532nm Potassium Titanyl Phosphate (KTP) Laser Treatment Versus Radiofrequency Microneedling in Combination With 532 KTP Laser for Erythematotelangiectatic or Papulopustular Rosacea
This study is testing if using radiofrequency microneedling, alone or with a special laser, can help adults with rosacea feel better and improve their skin.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Miami Academic / other |
| Locations | 1 site (Miami Beach, Florida) |
| Trial ID | NCT06801717 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of radiofrequency microneedling for treating erythematotelangiectatic and papulopustular rosacea. It will also explore the potential benefits of combining this treatment with the 532 nm KTP laser. The study will involve adult participants who meet specific health criteria and will assess both clinical outcomes and novel therapeutic strategies for rosacea management.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with a clinical diagnosis of erythematotelangiectatic or papulopustular rosacea.
Not a fit: Patients currently using oxymetazoline or brimonidine, or those with certain skin conditions or sensitivities, may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the management of rosacea symptoms for affected patients.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in using microneedling techniques for various skin conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female adult (\>18yo) subjects in general good health 2. Clinical and/or histologic diagnosis of erythematotelangiectatic or papulopustular rosacea. 3. Subject is able to understand and sign informed consent 4. Subject is able to complete the study and comply with study procedures Exclusion Criteria: 1. Patients currently utilizing oxymetazoline or brimonidine. 2. Presence of dermatoses that might interfere with diagnosis as determined by a study investigator 3. Presence of extreme light sensitivity, or conditions pre-disposing to light sensitivity such as but not limited to xeroderma pigmentosum 4. Any significant medical condition that may prevent the patient from participating in the study according to the investigator's assessment 5. History of poor wound healing or blood-clotting abnormality 6. History of keloid formation or hypertrophic scarring 7. Hypersensitivity or contraindication to local anesthetics as determined by the principal investigator or other medical professional. 8. Prisoners
Where this trial is running
Miami Beach, Florida
- University of Miami Dermatology Miami Beach Clinic — Miami Beach, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Ariel Eber, MD — University of Miami
- Study coordinator: Maria Muniz Muniz
- Email: mmuniz@med.miami.edu
- Phone: 305-689-2646
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.